Atara Biotherapeutics, Inc. (ATRA) Upgraded to “Hold” at Zacks Investment Research
According to Zacks, “Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company’s lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California. “
Other equities analysts have also issued research reports about the company. Canaccord Genuity set a $47.00 price objective on Atara Biotherapeutics and gave the company a buy rating in a research note on Monday, December 12th. Jefferies Group set a $23.00 price objective on Atara Biotherapeutics and gave the company a buy rating in a research note on Monday, December 12th. Finally, Goldman Sachs Group, Inc. (The) lowered Atara Biotherapeutics from a neutral rating to a sell rating and reduced their price objective for the company from $23.00 to $16.00 in a research note on Thursday, September 15th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. Atara Biotherapeutics currently has a consensus rating of Hold and a consensus target price of $25.86.
Atara Biotherapeutics (NASDAQ:ATRA) opened at 15.75 on Wednesday. The stock’s market capitalization is $454.55 million. The firm has a 50-day moving average price of $17.24 and a 200-day moving average price of $19.45. Atara Biotherapeutics has a 52 week low of $12.45 and a 52 week high of $25.73.
Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Friday, November 4th. The company reported ($0.88) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.78) by $0.10. Equities research analysts predict that Atara Biotherapeutics will post ($3.10) EPS for the current fiscal year.
WARNING: This piece of content was first reported by Watch List News and is the propert of of Watch List News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright and trademark law. The original version of this piece of content can be viewed at http://www.watchlistnews.com/atara-biotherapeutics-inc-atra-upgraded-to-hold-at-zacks-investment-research/1048363.html.
In related news, CFO John Mcgrath sold 5,000 shares of Atara Biotherapeutics stock in a transaction dated Wednesday, October 12th. The stock was sold at an average price of $17.47, for a total value of $87,350.00. Following the completion of the transaction, the chief financial officer now owns 96,823 shares in the company, valued at approximately $1,691,497.81. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Mitchall G. Clark sold 2,995 shares of Atara Biotherapeutics stock in a transaction dated Wednesday, November 16th. The shares were sold at an average price of $19.53, for a total value of $58,492.35. Following the completion of the transaction, the insider now owns 98,182 shares of the company’s stock, valued at approximately $1,917,494.46. The disclosure for this sale can be found here. 16.10% of the stock is owned by corporate insiders.
Several institutional investors have recently made changes to their positions in ATRA. FMR LLC raised its stake in Atara Biotherapeutics by 29.9% in the second quarter. FMR LLC now owns 3,125,407 shares of the company’s stock valued at $70,353,000 after buying an additional 720,313 shares during the period. Redmile Group LLC raised its stake in Atara Biotherapeutics by 5.9% in the second quarter. Redmile Group LLC now owns 2,408,970 shares of the company’s stock valued at $54,226,000 after buying an additional 133,205 shares during the period. Eagle Asset Management Inc. raised its stake in Atara Biotherapeutics by 0.8% in the third quarter. Eagle Asset Management Inc. now owns 980,673 shares of the company’s stock valued at $20,976,000 after buying an additional 8,081 shares during the period. BlackRock Fund Advisors raised its stake in Atara Biotherapeutics by 6.8% in the third quarter. BlackRock Fund Advisors now owns 976,087 shares of the company’s stock valued at $20,879,000 after buying an additional 62,165 shares during the period. Finally, Neuberger Berman Group LLC raised its stake in Atara Biotherapeutics by 9.5% in the third quarter. Neuberger Berman Group LLC now owns 688,715 shares of the company’s stock valued at $14,732,000 after buying an additional 59,595 shares during the period. Hedge funds and other institutional investors own 77.18% of the company’s stock.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.